IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for IDEAYA Biosciences in a report issued on Monday, June 9th. Cantor Fitzgerald analyst L. Watsek anticipates that the company will post earnings of ($2.18) per share for the year. The consensus estimate for IDEAYA Biosciences' current full-year earnings is ($3.07) per share.
IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same period last year, the business posted ($0.53) EPS.
A number of other equities analysts also recently commented on IDYA. JPMorgan Chase & Co. raised their price objective on shares of IDEAYA Biosciences from $63.00 to $66.00 and gave the stock an "overweight" rating in a report on Thursday, May 22nd. Stephens reissued an "overweight" rating and issued a $50.00 price target on shares of IDEAYA Biosciences in a research report on Friday, February 14th. Two analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $54.27.
Get Our Latest Analysis on IDEAYA Biosciences
IDEAYA Biosciences Trading Up 4.2%
IDYA stock traded up $0.92 during trading on Tuesday, reaching $22.63. 1,110,448 shares of the stock were exchanged, compared to its average volume of 1,021,636. IDEAYA Biosciences has a twelve month low of $13.45 and a twelve month high of $44.42. The company has a market capitalization of $1.98 billion, a P/E ratio of -6.86 and a beta of 0.04. The stock has a 50 day simple moving average of $18.36 and a 200-day simple moving average of $21.20.
Hedge Funds Weigh In On IDEAYA Biosciences
A number of hedge funds have recently added to or reduced their stakes in IDYA. Rhumbline Advisers boosted its position in shares of IDEAYA Biosciences by 0.5% during the 4th quarter. Rhumbline Advisers now owns 113,561 shares of the company's stock worth $2,919,000 after acquiring an additional 585 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in shares of IDEAYA Biosciences by 9.1% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 7,483 shares of the company's stock valued at $123,000 after purchasing an additional 627 shares in the last quarter. Daiwa Securities Group Inc. boosted its holdings in shares of IDEAYA Biosciences by 44.0% in the 4th quarter. Daiwa Securities Group Inc. now owns 2,792 shares of the company's stock valued at $72,000 after purchasing an additional 853 shares in the last quarter. Mariner LLC raised its holdings in shares of IDEAYA Biosciences by 9.8% during the 4th quarter. Mariner LLC now owns 9,775 shares of the company's stock worth $251,000 after buying an additional 869 shares in the last quarter. Finally, Assetmark Inc. lifted its position in shares of IDEAYA Biosciences by 2.5% during the 4th quarter. Assetmark Inc. now owns 45,269 shares of the company's stock worth $1,163,000 after buying an additional 1,084 shares during the last quarter. Institutional investors own 98.29% of the company's stock.
About IDEAYA Biosciences
(
Get Free Report)
IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.
Featured Articles
Before you consider IDEAYA Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEAYA Biosciences wasn't on the list.
While IDEAYA Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
